enGene (NasdaqCM:ENGN) 2026 Conference March 09, 2026 08:00 AM ET Company ParticipantsRon Cooper - President and CEOConference Call ParticipantsNone - AnalystNoneAnd, welcome.Ron CooperPleasure to be here. Thank you very much for the invitation.NoneWell, thanks for coming back. I remember the conversation last year, and a lot has happened since.Ron CooperIt's been a busy year, that's for sure.NoneAbsolutely. Maybe we can get started diving into the detalimogene program for non-muscle invasive bladder cancer ...

Summary of Certara's Conference Call Company Overview - **Company**: Certara - **Industry**: Healthcare technology and distribution, specifically focusing on biosimulation and drug development Key Financial Highlights - **Q4 Performance**: Revenue and EBITDA were in line with expectations, with organic software revenue growth of 7% for 2025, and EBITDA margin at 32%, which was at the high end of guidance [3][4] - **2026 Revenue Guidance**: Projected revenue growth is flat to 4%, influenced by a 1% organic TTM software bookings and a -6% year-on-year decline in Q4 software bookings [4][5] - **Services Revenue**: Low single-digit growth of about 3% over the last three years, with a strong December in services bookings indicating potential stability in the market [6][7] Market Dynamics - **Customer Dynamics**: Notable deceleration in software bookings attributed to macro customer reprioritization and a decrease in study counts on Pinnacle 21 [4][5] - **End Market Outlook**: Despite challenges, there is an expectation of a stable market with potential tailwinds, particularly in services [7][8] Product and Service Insights - **Software and Services**: Strong demand for Model-Informed Drug Development (MIDD) and biosimulation services, particularly in QSP, Simcyp, and PBPK services [12][13] - **AI Integration**: Certara is integrating AI capabilities into its products, with the launch of Certara IQ for QSP and enhanced functionalities in Phoenix Cloud [26][27] Leadership and Strategic Changes - **New CEO**: Jon Resnick's appointment is expected to bring a customer-centric approach and improve commercial execution [9][15] - **Operational Changes**: Focus on aligning incentives across software and services to enhance customer engagement and operational efficiency [16][17] Research and Development - **Investment in R&D**: Continued investment in R&D is planned, particularly in MIDD and biosimulation, while maintaining EBITDA margins between 30%-32% [19][20] - **Cost Management**: Identified $10 million in cost avoidance to support investments while maintaining financial discipline [21] Future Opportunities - **Biosimulation's Role**: Certara is positioned to lead in the shift towards biosimulation as a replacement for traditional animal model studies, aiming to help biopharma companies reduce R&D costs and time [38][39] - **M&A Potential**: Certara has a strong balance sheet and is open to tuck-in acquisitions while also considering share repurchase as a capital allocation strategy [48][49] Conclusion - Certara is navigating a challenging market environment with a focus on operational improvements, strategic investments in AI and R&D, and leveraging its leadership position in biosimulation to drive future growth. The company is optimistic about stabilizing market conditions and the potential for increased demand in its services and software offerings [50][51]

Summary of Universal Health Services (NYSE: UHS) Conference Call Company Overview - **Company**: Universal Health Services (UHS) - **Event**: 2026 Conference Call - **Date**: March 09, 2026 Key Points Acquisition of Talkspace - UHS announced the acquisition of Talkspace for $5.25 per share, totaling an enterprise value of approximately $840 million [2][3] - The acquisition aims to enhance UHS's presence in the outpatient behavioral health segment, particularly by leveraging Talkspace's network of 6,000 therapists [3][4] - Talkspace's existing payer relationships, including TRICARE, are expected to provide significant benefits to UHS [5] Outpatient Business Growth - The acquisition is seen as an accelerant for UHS's outpatient business, which has faced challenges due to limited access to therapists [2][3] - UHS has approximately 120 outpatient facilities and plans to open 10 new freestanding facilities annually for the next several years [29][32] - The company aims to provide a comprehensive range of behavioral health services, from inpatient to virtual care, addressing the needs of various patient populations [32] Financial Implications - The transaction is expected to be slightly accretive in the first 12 months, with increasing revenue synergies over the following years [7][12] - UHS's leverage will increase by about 0.3 times, bringing it to a pro forma level of approximately 2.1, which remains within the company's target range [9] - Talkspace's projected revenues for 2026 are estimated at $280 million, representing a 3.5% increase in UHS's behavioral revenue [12] Technology and Efficiency Improvements - UHS is focusing on driving productivity and efficiency through technology, including AI applications in revenue cycle management [35][36] - The company has implemented improvements in coding assistance and denial appeals, which have helped maintain a competitive position against payers [38][41] - UHS is also investing in AI technology to streamline operations and enhance productivity in various areas [43] Market Challenges and Headwinds - UHS anticipates a $75 million headwind in the acute segment due to the expiration of ACA subsidies, affecting approximately 25%-30% of HIX patients [49][50] - The company is monitoring the impact of these changes and expects to have more clarity in the coming months [51] New Hospital Openings - UHS opened Cedar Hill Medical Center in Washington, D.C., which faced initial losses but is expected to become profitable in 2026 [56] - The Palm Beach Gardens Hospital is anticipated to contribute positively to UHS's growth, despite initial startup costs [57] Additional Insights - The acquisition of Talkspace is viewed as a strategic move to enhance UHS's capabilities in virtual behavioral healthcare delivery, tapping into a growing market demand [17][19] - UHS's focus on outpatient growth and technology investments positions the company to adapt to changing market dynamics and patient preferences [13][36]

AT&T (NYSE:T) FY Conference March 09, 2026 08:00 AM ET Company ParticipantsPascal Desroches - Senior Executive Vice President and Chief Financial OfficerConference Call ParticipantsBryan Kraft - Lead Equity Research Analyst of Media, Cable, Telecom and Video GamesBryan KraftOkay. Good morning, everyone. Welcome to our conference this year. I'm Bryan Kraft. I cover media and telecom for Deutsche Bank on the equity side. I'd like to welcome everyone to conference, and I'd like to introduce our first speaker o ...

Akebia Therapeutics Conference Call Summary Company Overview - **Company**: Akebia Therapeutics (NasdaqCM:AKBA) - **Focus**: Development of therapies for kidney disease, particularly anemia in chronic kidney disease patients Key Strategic Areas 1. **Commercial Product - Vafseo**: - Aim to establish Vafseo as the standard of care for anemia in chronic kidney disease patients on dialysis [3][7] - Ongoing phase four and three B trials to generate necessary data for standardization [3] 2. **Commitment to Kidney Disease**: - Focus on expanding the pipeline related to kidney disease, including drugs like praliciguat and AKB-907 [3][4] 3. **Future Beyond Kidney Disease**: - Small investments in other areas such as aducanumab and retinopathy of prematurity [4] Vafseo Product Insights - **Mechanism**: Vafseo is a HIF-PH inhibitor that offers a new approach to managing anemia, with fewer dose titrations and easier administration for physicians [7][8] - **Clinical Data**: - Phase 3 study showed a statistically significant reduction in mortality and hospitalization rates [8] - An 8% decrease in hospitalization and a 15% cost reduction per patient per year, translating to approximately $3.7 billion savings if all eligible patients switched from ESAs to Vafseo [9][10] - **Market Potential**: - Post-TDAPA market opportunity estimated at $1 billion, with potential for Vafseo to be a $500 million product [26][30] Dosing Strategy - **TIW Dosing**: - Transitioning to TIW (three times a week) dosing to improve patient adherence and ease of use for nephrologists [12][14] - Ongoing studies (VOICE and VOCAL) to validate TIW dosing effectiveness [15][37] Pipeline Developments 1. **Praliciguat**: - Targeting focal segmental glomerulosclerosis (FSGS) with a unique mechanism of action [49][50] - Phase 2 trials initiated, with a focus on demonstrating efficacy in a high unmet need area [50] 2. **AKB-097**: - A complement inhibitor with a tissue-targeted effect, expected to have a better safety profile and dosing regimen compared to existing treatments [51][52] - Basket study planned for multiple indications, including IgAN and lupus nephritis, with data expected in 2027 [53][54] Financial Metrics and Market Perception - **Investor Metrics**: - Focus on increasing the number of prescribers and adherence rates for Vafseo [60] - Balanced capital allocation to support both Vafseo and the pipeline [61] - **Market Understanding**: - Complexity of dialysis reimbursement may lead to underappreciation of Akebia's market potential [62] - Emphasis on the importance of consistent revenue growth and pipeline visibility to attract investor confidence [63][64] Conclusion - Akebia Therapeutics is positioned to leverage its innovative product Vafseo and a robust pipeline to address significant unmet needs in kidney disease, with a clear strategy for market penetration and growth potential in a billion-dollar market.

Xenon Pharmaceuticals (NasdaqGM:XENE) Update / briefing March 09, 2026 08:00 AM ET Company ParticipantsAndrew Tsai - SVPBrian Abrahams - Global Managing Director and Sector Head Healthcare ResearchChristopher Kenney - Chief Medical OfficerColleen Alabiso - SVP of Corporate AffairsDarren Cline - Chief Commercial OfficerIan Mortimer - President and CEOPaul Matteis - Managing Director and Head of Biotech ResearchConference Call ParticipantsBrian Skorney - Senior Research AnalystJoseph Thome - Managing Director ...

Recursion Pharmaceuticals 2026 Conference Summary Company Overview - **Company**: Recursion Pharmaceuticals (NasdaqGS:RXRX) - **Date**: March 09, 2026 - **Focus**: Technology-enabled drug discovery, particularly in oncology and immunology Key Points Strategic Focus - Recursion is concentrating on three strategic areas: 1. Doubling down on proof points 2. Surgical investments in the platform 3. Pairing ambition with discipline [1][2][4] Pipeline Management - The company is implementing rapid go/no-go decisions across its programs, emphasizing data-driven decision-making [1][2] - The portfolio is showing increased velocity, synthesizing 90% fewer compounds to reach advanced candidates in about half the time compared to industry standards [2][4] Financial Guidance - For 2026, Recursion expects a gross burn of less than $390 million, excluding inflows from partnerships [6][7] - The company aims to maintain transparency and provide significant updates to annual guidance when necessary [6][7] Partnership Dynamics - Recursion has crossed over half a billion in upfront and milestone payments from partnerships, including significant contributions from Roche and Sanofi [11][12][16] - The Roche partnership focuses on novel targets, with $60 million received in milestones for two datasets [12] - Sanofi's partnership includes five different targets, with potential milestones of $343 million per program [16] Operational Efficiency - The company has reduced pro forma expenses by 35% and is focused on ensuring every dollar contributes to value creation [21][22] - Recursion has made significant investments in its wet and dry lab capabilities, which are crucial for generating high-quality datasets [29][32] Data Strategy - Recursion emphasizes the importance of proprietary data, holding 40 petabytes of data that enhances its drug discovery capabilities [32][54] - The company is actively seeking partnerships to enhance its data assets, focusing on depth and quality of datasets rather than just breadth [53][55] Talent Acquisition - The company faces challenges in recruiting talent proficient in both AI and drug discovery, emphasizing the need for "bilingual talent" [40][41] - Retaining talent involves creating a culture that values both scientific and AI expertise equally [44] Market Positioning - Recursion believes there is ample opportunity in drug discovery, as only about 3% of the genome has an approved drug, indicating a vast untapped market [64][65] - The company aims to leverage its unique data and technology stack to maintain a competitive edge in the industry [62][68] Future Financing - Recursion is exploring various financing options, including partnerships and potential equity or debt instruments, while maintaining a focus on non-dilutive capital [47][49] - The company is positioned to pivot quickly based on pipeline results, which will influence its financing strategy [47][48] Additional Insights - The integration of AI in drug discovery is seen as a critical differentiator for Recursion, allowing for more efficient and effective R&D processes [32][68] - The company is committed to continuous innovation and operational excellence, ensuring that investments are future-facing and aligned with strategic goals [22][29] This summary encapsulates the key discussions and insights from the Recursion Pharmaceuticals conference, highlighting the company's strategic direction, operational efficiencies, and market opportunities.

BioMarin Pharmaceutical Conference Call Summary Company Overview - **Company**: BioMarin Pharmaceutical (NasdaqGS: BMRN) - **Date**: March 09, 2026 - **Key Speakers**: Brian Mueller (CFO), Cristin Hubbard (CCO) Key Points Industry and Company Performance - BioMarin reported a **13% revenue growth** in 2025, with the Skeletal Conditions unit (including VOXZOGO) growing by **26%** and Enzyme Therapies by **9%** [4][5] - The company anticipates **high single-digit growth** for both Skeletal Conditions and Enzyme Therapies in 2026 [4] Strategic Growth Pillars - BioMarin's corporate strategy is built on three pillars: **growth, innovation, and value commitment** [4] - The company is preparing for the **Amicus acquisition** in Q2 2026, which is expected to enhance its portfolio with two high-growth products in rare genetic conditions [5] Product Pipeline and Innovations - Recent approval of **PALYNZIQ** for adolescents and upcoming **Phase 3 data readouts** for VOXZOGO in hypochondroplasia and BMN 401 for ENPP1 deficiency [5][6] - Ongoing development of **BMN 351** for Duchenne muscular dystrophy and **BMN 333**, a long-acting CNP for achondroplasia [6] Market Dynamics and Patient Retention - BioMarin is focused on patient retention for VOXZOGO, emphasizing that **efficacy and safety** are key factors influencing caregivers' decisions to switch therapies [10][11] - Approximately **two-thirds** of KOLs and caregivers believe that switching therapies is unlikely if patients are doing well on current treatments [11] Achondroplasia Market Insights - The company is working to build a broader health narrative around achondroplasia beyond just growth, focusing on overall health benefits [12][14] - BioMarin has a long history with VOXZOGO, having started its development program over **15 years ago**, and is now filing for full approval based on long-term data [20] Hypochondroplasia Opportunity - The Phase 3 trial for hypochondroplasia is expected to yield data in the **first half of 2026**, with strong enrollment indicating market excitement [25][26] - The company is focusing on **disease awareness** and improving the diagnosis journey for hypochondroplasia patients [28][30] Amicus Acquisition and Market Expansion - The acquisition of Amicus is expected to enhance BioMarin's market presence, with **Galafold** currently available in **40 countries** and BioMarin operating in **80** [38] - The integration of Amicus products is anticipated to unlock additional value through deeper market penetration and improved diagnosis efforts [39][43] Financial Projections - The Amicus acquisition may be slightly dilutive in **2026** but is expected to be accretive in the first 12 months and substantially accretive thereafter [45] - BioMarin expects **VOXZOGO revenues** in the second half of 2026 to exceed the first half, primarily due to international order timing [64][66] Manufacturing and Operational Strategy - BioMarin is recognized for its high-quality manufacturing capabilities and plans to leverage these skills for Amicus products, particularly POMP [51][53] Clinical Data and Future Expectations - Upcoming data cuts for **BMN 351** and pivotal Phase 3 data for **ENPP1 deficiency** are anticipated, with a focus on patient diagnosis and treatment initiation [54][57] Conclusion BioMarin Pharmaceutical is positioned for continued growth through strategic acquisitions, a robust product pipeline, and a commitment to enhancing patient care in rare genetic conditions. The company is focused on leveraging its manufacturing expertise and expanding its market presence while maintaining a strong emphasis on patient retention and treatment efficacy.

Summary of Lonza Investor Conference Call Company Overview - **Company**: Lonza Group AG - **Industry**: Contract Development and Manufacturing Organization (CDMO) Key Points from the Conference Call Divestment Announcement - Lonza announced the divestment of its Capsules & Health Ingredients (CHI) business to Lone Star Funds, marking a significant step in its transformation to a pure-play CDMO [2][3] - The enterprise value for CHI at closing is 2.3 billion CHF, with expected total proceeds at or above 3 billion CHF (approximately $4 billion) at full exit [4][11] Strategic Focus - The divestment is part of Lonza's strategy to focus solely on its CDMO business, which has been a core part of its vision since December 2024 [5][22] - Lonza has executed a total of four divestments to support this transformation over the past 1.5 years [3] Financial Implications - Lonza will receive upfront cash proceeds of 1.7 billion CHF and retain a 40% stake in CHI without management control [11][13] - The transaction will trigger an estimated non-cash impairment of 1.3 billion CHF, which will be reflected in the 2025 financials [12] Market Position and Growth - The CDMO market is valued at around $100 billion, with an underlying growth rate of 8%-10% [9] - Lonza aims to outpace market growth at low teens percentage over time, supported by its unique strengths referred to as the "Lonza Engine" [10][21] Capital Allocation Strategy - Proceeds from the CHI divestment will be used for targeted organic growth opportunities and bolt-on M&A acquisitions [16][19] - Lonza plans to return 500 million CHF to shareholders through a share buyback, expected to be executed within a year of the transaction closing [17][23] Future Outlook - Lonza is committed to investing 7 billion CHF in organic growth by 2030, with a focus on high-quality assets that complement its existing offerings [19][21] - The company anticipates sales growth of 11%-12% and further CORE EBITDA margin expansion to above 32% of sales in 2026 [22] Competitive Landscape - Lonza's divestment process was rigorous, focusing on execution speed, deal certainty, and the ability of interested parties to deliver on business cases [35] - The company is prepared to pursue both organic and inorganic growth strategies, with a particular interest in high-quality assets that synergize with existing operations [19][20] Additional Insights - Lonza's approach to capital expenditures will remain cautious, preferring to secure anchor customers for significant investments while also allowing for headroom in capacity planning [36][39] - The expected holding period for the CHI exit is estimated to be around 5-7 years, with anticipated returns of 10%-25% typical for private equity transactions [42] This summary encapsulates the key discussions and strategic directions outlined during the Lonza Investor Conference Call, highlighting the company's commitment to its CDMO business and future growth ambitions.

Summary of ASMPT Conference Call Industry and Company Overview - The focus is on the advanced packaging (AP) sector, which is expected to account for 35% of total revenue by 2026, with TCB equipment revenue growing over 50% year-on-year, contributing 10% to total revenue [2][4] - The company is engaged in semiconductor solutions and surface mount technology (SMT), with revenue contributions projected at 55% for SMT and 45% for semiconductor solutions by 2026 [4] Core Insights and Arguments - Strong order guidance for Q1 2026, with a projected 40% year-on-year and 20% quarter-on-quarter increase, marking the highest quarterly orders in nearly four years [2][5] - The gross margin for Q4 2025 was impacted by a one-time semiconductor inventory impairment, but excluding this, a moderate upward trend is expected [2][5] - The company is accelerating the divestiture of non-core assets, having completed the sale of AAMI and planning to sell NEXS in H1 2026, aiming to focus on core packaging operations [2][7] - TCB technology lifespan has been extended, with the total addressable market (TAM) revised to $1.6 billion by 2028, and orders for HBM4 12-layer equipment have been secured from Micron and SK Hynix [2][8] Additional Important Points - The company has made significant progress in the CtoW field, with two AOI devices entering TSMC's supply chain earlier than expected, aiming to regain market share lost to lower-priced competitors [2][8] - The net profit for Q4 2025 saw a significant boost from a one-time gain of HKD 1.11 billion from the sale of AAMI, affecting year-on-year comparability [6] - The divestiture strategy is aimed at enhancing performance flexibility and generating one-time disposal gains, with a focus on increasing the revenue share from advanced packaging and TCB [7][10] - The company anticipates a potential valuation uplift, with a target PE ratio of 30-35 times for 2027, indicating a potential upside of 30%-35% from the current valuation of 22 times PE [3][10]